Heart rate variability (HRV) is a noninvasive measure reflecting autonomic cardiac function that independently predicts death and arrhythmic complications in apparently healthy middle-age and elderly subjects ([@b40-ehp-116-1494]; [@b43-ehp-116-1494], [@b42-ehp-116-1494]). Disturbances in autonomous nervous system function reflected by decreased HRV may represent one pathway by which tobacco smoke, including second-hand smoke (SHS), and air pollutants trigger cardiovascular mortality and morbidity ([@b32-ehp-116-1494], [@b31-ehp-116-1494]). The specific mechanisms by which these inhalants affect neural control of the heart are the focus of ongoing research. One potentially important pathway is oxidative stress ([@b2-ehp-116-1494]; [@b3-ehp-116-1494]; [@b28-ehp-116-1494]), because inhaled smoke (and other pollutants) provokes oxidative stress and an inflammatory response in the lung and heart ([@b6-ehp-116-1494]; [@b14-ehp-116-1494]; [@b49-ehp-116-1494], [@b50-ehp-116-1494]). Although reactive oxygen species (ROS) have an established importance in the pathogenesis of cardiovascular diseases ([@b5-ehp-116-1494]), their specific impact on autonomous nervous system activity and its reaction to inhalants remains to be established. Recent studies provide evidence for oxidative stress as one of the mechanisms for the effect of air pollution on HRV ([@b3-ehp-116-1494]). We have demonstrated that the acute effect of particulate matter (PM) air pollution on HRV is modified by polymorphisms in the glutathione *S*-transferase (*GST*) gene *GSTM1* ([@b37-ehp-116-1494]) and the hemochromatosis gene *HFE* ([@b30-ehp-116-1494]), both exhibiting antioxidative properties ([@b10-ehp-116-1494]; [@b15-ehp-116-1494]; [@b30-ehp-116-1494]). Common polymorphisms in *GST* genes were previously found to modify respiratory effects of inhaled toxicants in children, asthmatics, smokers, and the general population ([@b12-ehp-116-1494]; [@b16-ehp-116-1494]; [@b20-ehp-116-1494]; [@b34-ehp-116-1494]) and to interact with tobacco smoke to increase the risk of coronary heart disease ([@b39-ehp-116-1494]). [@b35-ehp-116-1494] demonstrated that dietary supplementation with plant-derived n-3 polyunsaturated fatty acids, known for their antioxidative properties, abrogated the acute association between fine PM and decreased HRV in a cohort of elderly Mexicans. However, these studies have dealt with only acute exposure scenarios and short-term changes in HRV, whereas most studies have linked baseline HRV to cardiovascular risk ([@b40-ehp-116-1494]; [@b43-ehp-116-1494], [@b42-ehp-116-1494]).

To further investigate the hypothesis of an ROS impact on autonomous nervous system activity in the general population, we have investigated the association between polymorphisms in *GSTM1*, *GSTT1*, and *GSTP1* and changes in HRV in male and female participants in the population-based SAPALDIA cohort (Swiss Cohort on Air Pollution and Lung and Heart Disease in Adults) ≥ 50 years of age. To indirectly test whether the effects of SHS were mediated by oxidative stress, we also assessed the interaction of SHS with *GST* polymorphisms and obesity.

Materials and Methods
=====================

Study population
----------------

SAPALDIA was designed to measure the health effects of air pollutants and has been previously described ([@b1-ehp-116-1494]; [@b7-ehp-116-1494]; [@b26-ehp-116-1494]). Briefly, random samples of the Swiss population were recruited from eight areas featuring distinct geographic and environmental conditions. Participants were examined in 1991 and in 2001--2003. A random sample of follow-up participants ≥ 50 years of age participated in a 24-hr electrocardiogram recording (*n* = 1,837) ([@b8-ehp-116-1494], [@b9-ehp-116-1494]), including 1,133 nonsmoking subjects \[see Supplemental Material (<http://www.ehponline.org/members/2008/11402/suppl.pdf>) for exclusion criteria\]. The study protocol complied with all applicable ethical regulations. Participants gave written informed consent before the study. The study was approved by the Ethical Committee of the Swiss Academy of Medical Sciences and the eight cantonal ethical committees.

Interview, body mass index, and blood pressure
----------------------------------------------

SHS exposure was assessed at the in-person interview by asking subjects how many hours per day they were exposed to other people's tobacco smoke (*a*) at home, (*b*) at the workplace, (*c*) in bars and restaurants, or (*d*) elsewhere. We focused on SHS exposure at home and work because these two sources dominate overall exposure in most subjects. We classified subjects as not exposed, exposed ≤ 2 hr/day, or exposed \> 2 hr/day ([@b9-ehp-116-1494]). Weight, height, and body mass index (BMI; kg/m^2^) were based on measuring participants without them wearing any shoes or coats. Blood pressure was measured at rest in the sitting position on the left upper arm by an automatic device (705CP; OMRON, Steinhausen, Switzerland).

HRV parameters
--------------

For 24-hr electrocardiogram (Holter) recording, digital devices (Aria, Del Mar Medical Systems, Irvine, CA, USA) with a frequency response of 0.05--40 Hz and a resolution of 128 samples/sec were used ([@b8-ehp-116-1494], [@b9-ehp-116-1494]). The recorders were hooked up after the interview. Participants were asked to follow their regular daily life and to fill in a time--activity diary during recording time. Mean duration of the recordings was 22.3 ± 2.1 hr. All recordings were scanned through a StrataScan 563 (Del Mar). Mean heart rate per minute was derived from Holter measurements. Spectral analysis was performed by the fast Fourier transform method. Here we focus on the frequency-domain variables because they allow resolution of total HRV \[total power (TP); ≤ 0.40 Hz\] into a component primarily reflecting parasympathetic stimulation \[high-frequency (HF) power; 0.15--0.40 Hz\] and a component reflecting both sympathetic and parasympathetic influences \[low-frequency (LF) power; 0.04--0.15 Hz\] \[for methodological details, see Supplemental Material (online at <http://www.ehponline.org/members/2008/11402/suppl.pdf>); for results on time-domain parameters SDNN (standard deviation of all normal-to-normal intervals), SDANN (deviations of the normal-to-normal R-R period), and rMSSD (square root of the mean squared differences of successive R-R intervals), see Supplemental Material, [Tables 1](#t1-ehp-116-1494){ref-type="table"} and [2](#t2-ehp-116-1494){ref-type="table"}\].

Blood markers and genotype
--------------------------

All subjects were genotyped for *GSTM1* (UniGene ID Hs.301961; [@b44-ehp-116-1494]) and *GSTT1* (UniGene Hs.268573; [@b45-ehp-116-1494]) gene deletions and a single nucleotide polymorphism (SNP) in *GSTP1* (UniGene Hs.523836; [@b46-ehp-116-1494]) leading to the amino acid substitution Ile105Val, as previously described ([@b18-ehp-116-1494]) \[for details, see Supplemental Material (online at <http://www.ehponline.org/members/2008/11402/suppl.pdf>)\].

Statistical analysis
--------------------

We assessed the association of log-transformed HRV with *GST* genotypes, obesity, and SHS exposure by multiple regression analyses adjusting for study area, age (and its square), sex, diabetes, beta-blocker intake, and fruit intake. We present results as percent change in HRV parameters compared with the respective reference groups. To assess the interactions between SHS, *GST* genotypes, and obesity, we calculated trend tests by entering cross-categorized variables into the respective regression models. We coded the cross-categorized variables as 1 if both at-risk characteristics were absent, 2 if only one at-risk characteristic was present, and 4 if both at-risk characteristics were present in a subject. We performed statistical analysis using the software package SAS version 8.2 (SAS Institute, Inc., Cary, NC, USA) \[for details, see Supplemental Material (<http://www.ehponline.org/members/2008/11402/suppl.pdf>)\].

Results
=======

[Table 1](#t1-ehp-116-1494){ref-type="table"} presents characteristics of the study population, which have also been reported in more detail elsewhere ([@b9-ehp-116-1494]). In brief, 52% of the subjects included in the study were females. Mean age was 60.6 (SD 6.3) years, and mean BMI was 26.6 (4.2) kg/m^2^. Non-log-transformed means (SDs) for the different frequency-domain HRV parameters were TP, 4,583.1 msec^2^ (2,902.5); HF, 114.4 msec^2^ (235.0); and LF, 304.0 msec^2^ (275.9). SHS exposure either at work or at home was reported by 16% of the participants. In the present subpopulation of nonsmokers, 52% and 18% of subjects exhibited homozygous *GSTM1* and *GSTT1* gene deletion, respectively. Genotype distribution for the *GSTP1* Ile105Val SNP was 49% (Ile/Ile), 43% (Ile/Val), and 8% (Val/Val).

[Table 2](#t2-ehp-116-1494){ref-type="table"} presents the independent associations of *GST* genotypes, SHS, and obesity with changes in LF, HF, and TP HRV parameters. We observed no association for any of the predictors with HF values. *GSTT1* deficiency, \> 2 hr/day of SHS exposure, and obesity were each independently associated with lower TP and LF, and there was a trend toward an association of *GSTP1* (Ile105Val) with TP. TP and LF were each 10% lower among subjects homozygous for *GSTT1* gene deletion compared with participants without the deletion (*p* = 0.02 and 0.04). The associations between HRV and *GSTP1* were consistent with the *GSTT1* findings but did not reach statistical significance. *GSTM1* deficiency was not associated with changes in any HRV parameter. SHS (−17.6%, *p* = 0.006) and obesity (−15.0%, *p* = 0.0003) were associated with larger reductions in overall HRV (TP) than were the genotypes. The associations of *GST* genotypes, obesity, and SHS with HRV time-domain parameters were generally consistent in direction with those observed for frequency-domain parameters, but reached statistical significance only for the obesity association with both SDNN and SDANN \[see Supplemental Material, [Table 1](#t1-ehp-116-1494){ref-type="table"} (<http://www.ehponline.org/members/2008/11402/suppl.pdf>)\].

[Table 3](#t3-ehp-116-1494){ref-type="table"} and [Figure 1](#f1-ehp-116-1494){ref-type="fig"} present the two-way interactive effects of *GST* genotypes, SHS, and obesity on HRV frequency-domain parameters. To maximize power to detect an interaction, for these analyses we characterized SHS exposure as either high (≥ 2 hr/day) or not. We found significant two-way interactions for the effect of high SHS exposure and *GSTM1*, *GSTT1*, *GSTP1*, and obesity on TP. For example, subjects with the *GSTM1* deletion and high SHS exposure had a 26.3% reduction in TP (95% CI, −38.7% to −11.6%) ([Figure 1](#f1-ehp-116-1494){ref-type="fig"}), and obese subjects with high SHS exposure had a 24.1% reduction in TP (95% CI, −41.5% to −1.5%) compared with *GSTM1* carriers and no or low SHS or absence of obesity, respectively ([Figure 1](#f1-ehp-116-1494){ref-type="fig"}). In addition, for LF, two-way interactions were also significant for *GSTT1*, *GSTP1*, and obesity. In contrast, we saw no interactions for HF.

The interaction between *GSTT1* and SHS was subadditive rather than superadditive, as shown in [Table 3](#t3-ehp-116-1494){ref-type="table"}. Subjects with the gene and SHS had a 21.3% reduction in LF, subjects with the gene deletion but no/low SHS had a 12.1% reduction in TP, but subjects with both the high SHS exposure and the deletion only had a 6.7% reduction in TP.

Further, treating obesity as the exposure, we saw a significant two-way interaction with *GSTT1* for LF. In this case, the direction of the interaction was superadditive.

Although, generally, we observed no statistically significant interactions between *GST* genotypes, obesity, or SHS exposure and time-domain parameters, there was a suggestion for an elevated decrease in SDNN and SDANN among subjects exhibiting both *GSTM1* deletion genotype and high SHS exposure or obesity \[see Supplemental Material, [Table 2](#t2-ehp-116-1494){ref-type="table"} (<http://www.ehponline.org/members/2008/11402/suppl.pdf>)\].

The results presented above were unaltered when we adjusted them for any of the additional potential confounders listed under "Statistical analysis" (data not shown). Additional control for heart rate and systolic or diastolic blood pressure also did not materially alter these results. Additional analysis of HRV restricted to the sleep period according to diary information showed results similar to those achieved in the 24-hr analyses. On average, LF power was lower at night by 11.1% (*p* = 0.03) in the *GSTT1*-deficient group compared with the reference group.

Discussion
==========

We found associations between common *GST* gene variants that are involved in oxidant defense and HRV in the general population. Participants missing both copies of the *GSTT1* gene had, on average, 10% lower overall and LF-domain HRV. *GSTM1* deficiency and the *GSTP1* Ile105Val SNP were not independently associated with HRV changes, but we identified interactions between all three *GST* polymorphisms and exposure to SHS for effects on HRV. Combined with the interaction of SHS with obesity, a condition known to increase systemic oxidative stress, this provides support for the hypothesis that SHS affects HRV through oxidative stress pathways. This in turn implies that oxidative stress is an important modifier of the autonomic control of the heart, a hypothesis that has received little attention until recently.

The hypothesis of oxidative stress being a relevant pathophysiologic mechanism underlying individual variation in the functioning of the autonomous nervous system, and therefore HRV, is supported by (*a*) genetic polymorphisms related to oxidative defenses ([@b10-ehp-116-1494]; [@b15-ehp-116-1494]; [@b30-ehp-116-1494]) affecting HRV; (*b*) conditions likely to increase oxidative stress, such as obesity ([@b21-ehp-116-1494]) and SHS ([@b50-ehp-116-1494]), decreasing HRV; and (*c*) prooxidative conditions such as obesity and SHS interacting with genetic polymorphisms related to oxidative defenses.

Epidemiologic support for an association between oxidative stress and the autonomic control of the heart is still limited, but recent evidence is supportive of this hypothesis. Data in men from the Normative Aging Study recently provided strong evidence that oxidative stress may be a key pathway for the adverse effects of combustion particles on HRV ([@b37-ehp-116-1494]). The association between fine PM and reduced HRV was restricted to persons missing the *GSTM1* gene and persons likely to have greater than average baseline systemic inflammation and oxidative stress, such as the obese. Statins, a widely prescribed class of lipid-lowering drugs with substantial antiinflammatory and antioxidant activity, protected *GSTM1*-deficient subjects against the effects of fine PM ([@b37-ehp-116-1494]). One key difference in our study is that we aimed to assess the effect of a chronic exposure (SHS, obesity) on baseline HRV, rather than an acute one. Although some of the observed associations can still be attributed to acute effects due to collinearity between chronic and acute exposure, the association with chronic exposure suggests an ongoing and not a transitory impact on HRV, which may have more public health relevance. On the other hand, the similarity between SHS and ambient PM is sufficiently high that the finding of interactions of *GSTM1* status and obesity with these exposures in two separate cohorts argues against this being a chance finding.

The association of chronic stimuli such as obesity, insulin resistance, and diabetes with reduced HRV ([@b11-ehp-116-1494]) is also compatible with an ROS impact on the autonomic nervous system. In nondiabetic human subjects, fat accumulation and obesity are closely correlated with markers of systemic oxidative stress ([@b21-ehp-116-1494]; [@b29-ehp-116-1494]). Diabetic patients are known to have elevated oxidative stress levels, and they also exhibit increased susceptibility to the effect of air pollution on HRV ([@b48-ehp-116-1494]). Chronic administration of the antioxidant vitamin E in a double-blind randomized controlled trial in patients with type 2 diabetes and cardiac autonomic neuropathy improved the ratio of the cardiac sympathetic to parasympathetic tone ([@b25-ehp-116-1494]). Marine- and plant-derived omega-3 fatty acid supplementation in elderly nursing home residents was associated with a significant increase in HRV ([@b17-ehp-116-1494]). The omega-3 fatty acid effects are possibly attributable in part to their antioxidative properties ([@b27-ehp-116-1494]).

The exact mechanisms by which ROS and associated inflammatory mediators affect the autonomous nervous system and its correlate HRV are still poorly understood and likely complex. Oxidants and inflammatory mediators can act directly in the brain, as evidenced by the involvement of oxidative stress in various neurodegenerative diseases such as Alzheimer's and Parkinson's disease ([@b4-ehp-116-1494]). Inflammatory markers, including interleukin-6, are present in the brain, where they can influence the autonomic balance ([@b19-ehp-116-1494]). A central nervous system effect of ROS is also compatible with results from a recent investigation in spontaneously hypertensive rats that are characterized by elevated oxidative stress ([@b13-ehp-116-1494]). The antioxidants *N*-acetylcysteine and melatonin restored cardiac baroreflex to normal, but not blood pressure, an effect that could be attributable to a central nervous system ROS effect. Interestingly, these rats were characterized by a primarily sympathetic defect, and our study finds the effects of SHS, obesity, and *GST* polymorphisms are absent for HF, which reflects a primarily parasympathetic response.

Finally, ROS and inflammatory markers may further exacerbate the autonomic disturbances on the heart through peripheral local effects on heart structures ([@b24-ehp-116-1494]), because oxidative stress is the most commonly hypothesized mechanism by which several cytotoxic anticancer drugs cause cardiotoxicity ([@b38-ehp-116-1494]). [@b41-ehp-116-1494] describes the central role of the autonomous nervous system in monitoring as well as regulating oxidative stress and inflammation at innervated pulmonary and extrapulmonary sites as the inflammatory reflex. In accordance with the inflammatory reflex model and our results, recent studies in rats intratracheally exposed to urban PM suggested a pulmonary-to-cardiac signaling model with pulmonary oxidants increasing cardiac oxidant concentrations under the strict control of the autonomous nervous system. Cardiac oxidative stress was preventable by both *N*-acetylcysteine and β~1~ receptor antagonist pretreatment of these animals ([@b33-ehp-116-1494]).

The respective impact of the different *GST* polymorphisms on HRV observed in this study further elucidates ROS mechanisms. The *GST* genes and isozymes exhibit differences in tissue expression as well as substrate specificity ([@b10-ehp-116-1494]; [@b15-ehp-116-1494]). Although liver is the only rich source of the *GSTM1* isozyme, where it is the predominant form, *GSTP1* and *GSTT1* are expressed in various tissues, including heart, brain, lung, and liver ([@b15-ehp-116-1494]; [@b36-ehp-116-1494]). The presence of *GSTT1* and---statistically nonsignificant---*GSTP1* main effects and the absence of a *GSTM1* main effect on HRV are consistent with an impact of locally and endogenously produced ROS in lung, heart, brain, and possibly additional organs on the activity of the autonomous nervous system. The hypothesis that endogenously produced oxidative stress affects the nervous system is further supported by the observation that lack of *GSTT1*, but not of other *GST* variants, is generally associated with increased susceptibility to brain diseases, including brain tumors and neurodegenerative diseases, even in apparently unexposed individuals ([@b22-ehp-116-1494]).

The modifying effect of *GSTM1* for the association of SHS with HRV suggests that these exposures cause systemic oxidative stress that is being scavenged by *GSTM1* in the liver. The modification of the SHS effect by *GSTM1* is consistent with previous studies on the association between SHS, *GST* polymorphisms, and lung cancer in never smokers ([@b47-ehp-116-1494]) and may reflect the additional impact of *GSTM1* on liver metabolism of tobacco-derived electrophils ([@b15-ehp-116-1494]; [@b22-ehp-116-1494]; [@b36-ehp-116-1494]). The modifying effect of *GSTP1* variants suggests that oxidative stress in target tissues other than liver is also important for the effects of SHS. The observation of subadditive effects of *GSTT1* and SHS, in contrast to the superadditive effects of *GSTT1* and obesity, suggest that some specific components of SHS drive the direction of the interaction. Depending on the substrate, *GSTT1*-catalyzed reactions can actually increase toxicity ([@b22-ehp-116-1494]). What that component is remains to be determined.

This study has a number of limitations. In all genetic studies, the prevalence of the polymorphism can limit power. A greater concern in this study is the 6.9% prevalence rate for high SHS exposure, which clearly limits power in gene-by-environment interactions. An additional limitation of this study is its cross-sectional design. We recorded electrocardiograms once for each subject. The future longitudinal assessment at the next follow-up examination will allow for improved adjustment of within-subject variation and allow us to examine differences in baseline autonomic function over time. The aging of the cohort will provide information on the combined impact of modifiable and genetic factors on the course of HRV decline and on the incidence of cardiac diseases. Finally, although the reported associations were comparable for frequency- and time-domain parameters, they were generally stronger and more consistent in the frequency domain.

However, the focus on frequency-domain parameters seems justified. First, the frequency-domain parameter HF captures the vagal, parasympathetic response more clearly than does rMSSD. Second, the Fourier transformation for TP, but not SDNN, is for a specified frequency range that trims off some ultra-HF signals. Extending the upper limit of the HF component, which is implicitly lacking in SDNN, beyond 0.4 Hz would be applicable only to extreme tachypnea of \> 24 respiratory cycles per minute. This is linked to extreme sympathetic overdrive, under which it is rather difficult to interpret the HF component. Moreover, because the cardiac period signal is discrete rather than continuous, it is difficult to properly estimate respiratory arrhythmia under such conditions of very fast tachypnea.

In conclusion, our results are consistent with an important role of oxidative stress in the autonomic control of the heart and, possibly, in individual variability in autonomous nervous system activity. If confirmed by additional studies specifically investigating the association between systemic oxidative stress markers and HRV, these findings have substantial public health relevance. [@b42-ehp-116-1494] suggested that a 1-SD reduction in overall HRV was associated with a relative risk of 1.47 for cardiac events over 3.5 years of follow-up. Although differences in study design preclude a quantitative risk estimate, the observed reduction in overall HRV in subjects with SHS exposure (\>2 hr) and either obesity, *GSTM1* deletion, or *GSTP1* substitution in our study suggests a nontrivial elevation of cardiovascular risk on follow-up, and one similar to what has in fact been reported for SHS exposure ([@b23-ehp-116-1494]).
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###### 

Characteristics of the study population: the SAPALDIA cohort study.

  Characteristic                                             Value
  ---------------------------------------------------------- -----------------
  Total \[no. (%)\]                                          1,133 (100.0)
  Female sex \[no. (%)\]                                     594 (52.4)
  Age \[years (mean ± SD)\]                                  60.6 ± 6.3
  BMI \[kg/m^2^ (mean ± SD)\]                                26.6 ± 4.2
   ≥ 30 kg/m^2^ \[no. (%)\]                                  223 (19.7)
  SHS exposure \[no. (%)\]                                   
   None                                                      956 (84.5)
   ≤ 2 hr/day                                                99 (8.7)
   \> 2 hr/day                                               78 (6.9)
  Diabetes \[no. (%)\]                                       41 (3.6)
  Medication \[no. (%)\]                                     
   Beta-blocker                                              135 (11.9)
   ACE inhibitor                                             70 (6.2)
   Antiarrhythmics, classes I + III                          5 (0.4)
   Calcium-channel blocker                                   53 (4.7)
   Diuretics                                                 42 (3.7)
   Sympathomimetics                                          37 (3.3)
  Uric acid \[μmol/L (mean ± SD)\]                           323.6 ± 81.6
  High-sensitivity C-reactive protein \[mg/L (mean ± SD)\]   2.5 ± 5.8
  Non-HDL cholesterol \[mmol/L (mean ± SD)\]                 4.7 ± 1.1
  Blood pressure \[mmHg (mean ± SD)\]                        
   Systolic                                                  132.5 ± 19.3
   Diastolic                                                 81.9 ± 10.6
  Heart rate \[bpm (mean ± SD)\]                             73.5 ± 9.0
  HRV (mean ± SD)                                            
   TP (msec^2^)                                              4583.1 ± 2902.5
   LF power (msec^2^)                                        304.0 ± 275.9
   HF power (msec^2^)                                        114.4 ± 235.0
   SDNN (msec)                                               138.7 ± 36.5
   SDANN (msec)                                              125.6 ± 35.0
   rMSSD (msec)                                              26.2 ± 14.9
  Genotypes \[no. (%)\]                                      
   *GSTM1* deletion                                          594 (52.4)
   *GSTT1* deletion                                          199 (17.6)
   *GSTP1*                                                   
    Ile/Ile                                                  550 (48.5)
    Ile/Val                                                  485 (42.8)
    Val/Val                                                  98 (8.7)

###### 

Percent difference (95% CI)[a](#tfn1-ehp-116-1494){ref-type="table-fn"} in HRV parameters according to *GST* genotypes, SHS, and obesity: the SAPALDIA cohort study.

  Genotype/exposure                                                       LF power                 HF power               TP
  ----------------------------------------------------------------------- ------------------------ ---------------------- -----------------------
  *GSTM1*                                                                                                                 
   Deletion vs. no deletion[b](#tfn2-ehp-116-1494){ref-type="table-fn"}   −1.7 (−9.3 to 6.4)       −1.6 (−11.2 to 9.0)    −2.6 (−9.1 to 4.4)
  *GSTT1*                                                                                                                 
   Deletion vs. no deletion[b](#tfn2-ehp-116-1494){ref-type="table-fn"}   −10.7 (−19.6 to −0.7)    −3.4 (−15.6 to 10.5)   −10.4 (−18.2 to −1.9)
  *GSTP1* to Ile105Val                                                                                                    
   Ile/Ile,Val vs. Val/Val                                                −7.9 (−20.1 to 6.2)      −8.6 (−23.8 to 9.7)    −10.6 (−20.9 to 1.1)
  SHS exposure                                                                                                            
   ≤ 2 hr/day vs. none                                                    −10.3 (−22.3 to 3.5)     −13.0 (−27.5 to 4.6)   −4.3 (−15.5 to 8.2)
   \> 2 hr/day vs. none                                                   −16.4 (−28.8 to −1.9)    −2.6 (−20.6 to 19.6)   −17.6 (−28.3 to −5.4)
  Obesity                                                                                                                 
   ≥ 30 vs. \< 30 kg/m^2^                                                 −19.5 (−27.4 to −10.8)   −5.0 (−16.7 to 8.4)    −15.0 (−22.2 to −7.2)

Adjusted for study area, sex, age and (age)^2^, fruit intake, diabetes, and beta-blocker intake and mutually adjusted for each other.

Homozygous gene deletion.

###### 

Percent difference (95% CI)[a](#tfn3-ehp-116-1494){ref-type="table-fn"} in HRV parameters according to combination of *GST* genotypes with passive smoking and obesity: the SAPALDIA cohort study.

  Genotype                                                           Exposure     No.   LF power                 HF power                TP
  ------------------------------------------------------------------ ------------ ----- ------------------------ ----------------------- ------------------------
  *GSTM1*                                                                                                                                
   No deletion                                                       No/low SHS   504   Referent                 Referent                Referent
   No deletion                                                       High SHS     35    −11.5 (−30.0 to 27.7)    −2.2 (−12.0 to 8.7)     −4.6 (−22.0 to 16.7)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              No/low SHS   551   −1.2 (−9.0 to 7.3)       −5.5 (−30.0 to 27.7)    −0.8 (−7.7 to 6.4)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              High SHS     35    −19.9 (−35.4 to −0.7)    1.6 (−22.8 to 33.9)     −26.3 (−38.7 to −11.4)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.094                    0.86                    0.014
   No deletion                                                       Not obese    437   Referent                 Referent                Referent
   No deletion                                                       Obese        102   −13.3 (−25.3 to 0.7)     1.6 (−16.2 to 23.0)     −3.0 (−14.7 to 10.4)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Not obese    473   1.2 (−7.5 to 10.6)       1.0 (−16.2 to 23.0)     2.4 (−5.2 to 10.6)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Obese        121   −23.5 (−33.4 to −12.0)   −9.4 (−24.2 to 8.2)     −22.1 (−30.9 to −12.1)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.16                     0.69                    0.25
  *GSTT1*                                                                                                                                
   No deletion                                                       No/low SHS   871   Referent                 Referent                Referent
   No deletion                                                       High SHS     63    −17.6 (−30.9 to −1.7)    −3.0 (−22.6 to 21.5)    −21.3 (−32.3 to −8.5)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              No/low SHS   184   −11.1 (−20.2 to −0.7)    −4.1 (−16.7 to 10.3)    −12.1 (−20.0 to −3.5)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              High SHS     15    −16.5 (−41.1 to 18.5)    6.9 (−31.8 to 67.4)     −6.7 (−30.9 to 25.9)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.007                    0.77                    0.002
   No deletion                                                       Not obese    748   Referent                 Referent                Referent
   No deletion                                                       Obese        186   −18.1 (−26.7 to −8.4)    −5.3 (−18.0 to 9.3)     −15.1 (−22.9 to −6.4)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Not obese    162   −8.7 (−18.8 to 2.6)      −3.5 (−16.9 to 12.1)    −10.3 (−19.0 to −0.8)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Obese        37    −33.1 (−46.7 to −16.0)   −7.3 (−30.8 to 24.0)    −24.5 (−37.9 to −8.1)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.011                    0.79                    0.084
  *GSTP1*, Ile105Val                                                                                                                     
   Val/Val                                                           No/low SHS   87    Referent                 Referent                Referent
   Val/Val                                                           High SHS     11    −16.9 (−45.9 to 27.7)    13.4 (−34.6 to 99.5)    −9.4 (−37.3 to 32.0)
   Ile/Ile, Val                                                      No/low SHS   969   −7.9 (−20.7 to 7.0)      −6.5 (−22.9 to 13.3)    −9.7 (−20.6 to 2.7)
   Ile/Ile, Val                                                      High SHS     67    −22.6 (−37.8 to −3.6)    −9.4 (−31.6 to 19.9)    −26.4 (−39.1 to −11.2)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.020                    0.53                    0.011
   No deletion                                                       Not obese    79    Referent                 Referent                Referent
   No deletion                                                       Obese        19    −2.2 (−30.7 to 38.0)     6.6 (−31.4 to 65.6)     10.5 (−17.9 to 48.8)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Not obese    831   −4.1 (−18.1 to 12.4)     −6.3 (−23.5 to 14.7)    −5.5 (−17.5 to 8.4)
   Deletion[b](#tfn4-ehp-116-1494){ref-type="table-fn"}              Obese        204   −24.1 (−36.5 to −9.2)    −11.9 (−29.9 to 10.8)   −21.8 (−32.8 to −8.5)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.073                    0.66                    0.33
  Obesity                                                                                                                                
   No/low SHS                                                        Not obese    855   Referent                 Referent                Referent
   No/low SHS                                                        Obese        200   −1.2 (−18.0 to 19.1)     9.9 (−13.5 to 29.1)     −12.1 (−25.2 to 3.2)
   High SHS                                                          Not obese    55    −3.4 (−17.4 to 13.0)     5.6 (−13.7 to 29.1)     5.4 (−7.9 to 20.7)
   High SHS                                                          Obese        23    −44.4 (−58.9 to −24.8)   −18.6 (−44.9 to 20.0)   −24.1 (−41.5 to −1.5)
   *p*-Value for trend[c](#tfn5-ehp-116-1494){ref-type="table-fn"}                      0.002                    0.76                    0.049

Adjusted for study area, sex, age and (age)^2^, fruit intake, diabetes, and beta-blocker intake and mutually adjusted for each other. We did not mutually adjust *GST* polymorphisms for each other. We adjusted *GST*/SHS models for BMI as a continuous variable, and adjusted *GST*/obesity models for SHS.

Homozygous deletion.

We derived the *p*-values for trend by entering a cross-categorized variable coded as 1, 2, and 4 for subjects exhibiting 0, 1, or 2 at-risk characteristics, respectively.

[^1]: The authors declare they have no competing financial interests.
